Vaxxinity
VAXX · OTC
Share price · VAXX
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when VAXX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 14 Aug 2026+25400.0%
Nothing announced by VAXX that day or the session before.
- 2 Jul 2026+16650.0%
Nothing announced by VAXX that day or the session before.
- 18 Jun 2026+14900.0%
Nothing announced by VAXX that day or the session before.
- 15 Jun 2026+19900.0%
Nothing announced by VAXX that day or the session before.
- 9 Jun 2026+7400.0%
Nothing announced by VAXX that day or the session before.
- 27 Apr 2026+19900.0%
Nothing announced by VAXX that day or the session before.
- 20 Apr 2026+9900.0%
Nothing announced by VAXX that day or the session before.
- 1 Apr 2026+9900.0%
Nothing announced by VAXX that day or the session before.
- 11 Mar 2026+9900.0%
Nothing announced by VAXX that day or the session before.
- 4 Feb 2026+22150.0%
Nothing announced by VAXX that day or the session before.
Share of unusual movement by asset
For each asset, the share of VAXX's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
| Other company news (earnings, financing, releases naming no asset) | — | 0% |
| Sessions with no dated event | — | 100% |
No dated announcements about its assets since 2 Jul 2024.
Assets
(2 total)
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Financial reports
Quarterly & interim (7)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2023-Q3 | — | $7.9M | $18M+ $25M short-term inv. | $13M-$13M operating cash flow | report ↗ |
Vaxxinity reported R&D spend of $7.91M, down 36.6% YoY, cash and equivalents of $17.6M, and a net loss of $13.14M for Q3 2023.
Figures only: this period's report disclosed no narrative text
View 6 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2023-Q2 | — | $8.3M | $37M+ $19M short-term inv. | $14M-$12M operating cash flow | report ↗ |
| 2023-Q1 | — | $11M | $23M+ $45M short-term inv. | $18M-$20M operating cash flow | report ↗ |
| 2022-Q3 | — | $12M | $22M+ $80M short-term inv. | $19M-$11M operating cash flow | report ↗ |
| 2022-Q2 | $0.1M | $11M | $114M | $17M-$11M operating cash flow | report ↗ |
| 2022-Q1 | — | $11M | $125M | $18M-$20M operating cash flow | report ↗ |
| 2021-Q3 | $0.1M | $24M | $89M | $30M-$21M operating cash flow | report ↗ |
Annual history (3 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2023-FY | — | $36M | $5.0M+ $25M short-term inv. | $14M-$57M operating cash flow | report ↗ |
Insider transactions
Insider-transaction reporting (SEC Form 4) applies to US-listed SEC filers. No SEC insider-filing record exists for this company's listing.
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 1 reporting institution held 0.0M shares ($43).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | NBC SECURITIES, INC. | 1,592 | $43 |